TripSitter Announces Discovery Notice

• TripSitter Clinic Ltd. was identified as a respondent in discovery regarding a negligence and wrongful death lawsuit filed in Illinois on April 20, 2026.
• The company is explicitly not named as a defendant in the lawsuit.
• There are no allegations of wrongdoing directed at the Company by the plaintiffs.
• Management is currently seeking legal advice concerning its obligations as a respondent in the discovery process.
• This follows a series of capital events including debt settlements via equity issuance and a small private placement financing announced on April 13, 2026.

• The news introduces legal uncertainty but does not confirm direct liability or financial loss at this stage.
• Being a respondent in discovery for a wrongful death case is reputational risk, even if not the primary defendant; it suggests operational scrutiny in Illinois which may be outside their core jurisdiction (CSE listed).
• The immediate material impact is limited compared to the preceding debt-for-equity settlements ($665k+ settled via shares), which indicate severe cash flow constraints.
• The financing news from April 13 raised $200k target but resulted in significant dilution, already priced into the recent price action of $0.14.
• Legal discovery adds a layer of opacity to management's risk profile without changing the fundamental solvency picture established by previous debt settlements.

• TripSitter Clinic Ltd. operates as a medical clinic service provider, likely focused on patient care management or specialized health services.
• The company has been actively managing liabilities through equity issuance rather than cash payments.
• No specific "flagship project" is detailed in the news releases; operations appear to be ongoing clinical services.
• The company trades on the Canadian Securities Exchange (CSE), indicating a smaller cap, higher risk profile.